Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17588564rdf:typepubmed:Citationlld:pubmed
pubmed-article:17588564lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17588564lifeskim:mentionsumls-concept:C0917798lld:lifeskim
pubmed-article:17588564lifeskim:mentionsumls-concept:C1720997lld:lifeskim
pubmed-article:17588564lifeskim:mentionsumls-concept:C0205234lld:lifeskim
pubmed-article:17588564lifeskim:mentionsumls-concept:C0598958lld:lifeskim
pubmed-article:17588564lifeskim:mentionsumls-concept:C0205421lld:lifeskim
pubmed-article:17588564pubmed:issue1-3lld:pubmed
pubmed-article:17588564pubmed:dateCreated2007-8-20lld:pubmed
pubmed-article:17588564pubmed:abstractTextIn gerbils subjected to transient global cerebral ischemia, melanocortin peptides produce long-lasting protection with a broad time window, and through the activation of central nervous system melanocortin MC(4) receptors. Here we aimed to investigate whether melanocortins are neuroprotective also in a rat model of focal cerebral ischemia induced by intrastriatal microinjection of endothelin-1. The vasoconstrictor agent endothelin-1 caused a significant impairment in spatial learning and memory, as well as in sensory-motor orientation and limb use, associated with severe striatal morphological damage including intense neuronal death and an almost complete myelin degradation. Treatment of ischemic rats with a nanomolar dose (340 microg/kg/day i.p. for 11 days, beginning 3 h or 9 h after endothelin-1 microinjection) of the melanocortin analog [Nle(4), D-Phe(7)]alpha-melanocyte-stimulating hormone (NDP-alpha-MSH) significantly reduced striatal damage, and improved subsequent functional recovery, with all scheduled NDP-alpha-MSH treatments. Pharmacological blockade of melanocortin MC(4) receptors prevented the protective effect of NDP-alpha-MSH. Our findings give evidence that melanocortins are neuroprotective, with a broad time window, also in a severe model of focal cerebral ischemia, and suggest that melanocortin MC(4) receptor agonists could produce neuroprotection in different experimental models of ischemic stroke.lld:pubmed
pubmed-article:17588564pubmed:languageenglld:pubmed
pubmed-article:17588564pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17588564pubmed:citationSubsetIMlld:pubmed
pubmed-article:17588564pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17588564pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17588564pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17588564pubmed:statusMEDLINElld:pubmed
pubmed-article:17588564pubmed:monthSeplld:pubmed
pubmed-article:17588564pubmed:issn0014-2999lld:pubmed
pubmed-article:17588564pubmed:authorpubmed-author:ZaffeDavideDlld:pubmed
pubmed-article:17588564pubmed:authorpubmed-author:BazzaniCarlaClld:pubmed
pubmed-article:17588564pubmed:authorpubmed-author:MioniChiaraClld:pubmed
pubmed-article:17588564pubmed:authorpubmed-author:GuariniSalvat...lld:pubmed
pubmed-article:17588564pubmed:authorpubmed-author:SquadritoFran...lld:pubmed
pubmed-article:17588564pubmed:authorpubmed-author:OttaniAlessan...lld:pubmed
pubmed-article:17588564pubmed:authorpubmed-author:GiulianiDanie...lld:pubmed
pubmed-article:17588564pubmed:authorpubmed-author:MinutoliLette...lld:pubmed
pubmed-article:17588564pubmed:authorpubmed-author:BittoAlessand...lld:pubmed
pubmed-article:17588564pubmed:authorpubmed-author:BotticelliAnn...lld:pubmed
pubmed-article:17588564pubmed:authorpubmed-author:GalantucciMar...lld:pubmed
pubmed-article:17588564pubmed:issnTypePrintlld:pubmed
pubmed-article:17588564pubmed:day10lld:pubmed
pubmed-article:17588564pubmed:volume570lld:pubmed
pubmed-article:17588564pubmed:ownerNLMlld:pubmed
pubmed-article:17588564pubmed:authorsCompleteYlld:pubmed
pubmed-article:17588564pubmed:pagination57-65lld:pubmed
pubmed-article:17588564pubmed:meshHeadingpubmed-meshheading:17588564...lld:pubmed
pubmed-article:17588564pubmed:meshHeadingpubmed-meshheading:17588564...lld:pubmed
pubmed-article:17588564pubmed:meshHeadingpubmed-meshheading:17588564...lld:pubmed
pubmed-article:17588564pubmed:meshHeadingpubmed-meshheading:17588564...lld:pubmed
pubmed-article:17588564pubmed:meshHeadingpubmed-meshheading:17588564...lld:pubmed
pubmed-article:17588564pubmed:meshHeadingpubmed-meshheading:17588564...lld:pubmed
pubmed-article:17588564pubmed:meshHeadingpubmed-meshheading:17588564...lld:pubmed
pubmed-article:17588564pubmed:meshHeadingpubmed-meshheading:17588564...lld:pubmed
pubmed-article:17588564pubmed:meshHeadingpubmed-meshheading:17588564...lld:pubmed
pubmed-article:17588564pubmed:meshHeadingpubmed-meshheading:17588564...lld:pubmed
pubmed-article:17588564pubmed:year2007lld:pubmed
pubmed-article:17588564pubmed:articleTitleNeuroprotection in focal cerebral ischemia owing to delayed treatment with melanocortins.lld:pubmed
pubmed-article:17588564pubmed:affiliationDepartment of Biomedical Sciences, Section of Pharmacology, University of Modena and Reggio Emilia, Modena, Italy.lld:pubmed
pubmed-article:17588564pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17588564pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed